constant diarrhea glp 1 As GLP-1 use expands beyond diabetes and obesity, clinicians are seeing a wider range of real-world symptoms, including reports of chronic cough. Observational data suggest a higher incidence of persistent cough with Battling a bad case of

The July 2025 change kept Wegovy (and Saxenda) on the standard formulary, with prior authorization under the same BMI and 6-month-program structure

As the therapy persists, combined behavioral and metabolic effects foster substantial, sustainable weight loss maintained by continued use

Multiple logistic regression was used to estimate the standardized 1year risk, risk difference (average treatment effect among GLP1 RA initiators), and risk ratio (RR) using the gformula, 27 where the reference population included all patients in the subgroups

There are weekly injectables currently, and more in development

J Endocrinol 202(3):431439